InfoBionic™ is an emerging healthcare technology company aimed at improving mobile patient monitoring solutions announced the closing of a $17 million Series B financing with Safeguard Scientifics, Inc. (NYSE: SFE). The funds raised will be used to bring InfoBionic’s new ambulatory cardiac monitor, the MoMe™ to the estimated $3 Billiong dollar market place worldwide.
InfoBionic’s MoMe™ device is a remote patient monitoring platform for cardiac arrhythmia detection, in Europe and the United States. The proprietary platform uses cloud-based technology to improve remote patient monitoring and reduce operating and healthcare costs. The MoMe provides unprecedented analytics with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) monitoring modes in one device. MoMe Kardia is poised to revolutionize cardiac monitoring technology by delivering superior arrhythmia detection and on-demand access to patient data for diagnosis. InfoBionic annouced the CE™ mark for its MoMe™ device earlier this year.
As part of this financing, Safeguard Scientifics acquired 20% primary ownership of InfoBionic and Mr. Wiegman will join InfoBionic’s board of directors.
